MCT4 blockade increases the efficacy of immune checkpoint blockade

URN to cite this document:: urn:nbn:de:bvb:355-epub-549260
DOI to cite this document:: 10.5283/epub.54926

Babl, Nathalie ; Decking, Sonja-Maria ; Voll, Florian ; Althammer, Michael ; Sala-Hojman, Ada ; Ferretti, Roberta ; Korf, Clarissa ; Schmidl, Christian ; Schmidleithner, Lisa ; Nerb, Benedikt ; Matos, Carina

; Koehl, Gudrun E. ; Siska, Peter J.

; Bruss, Christina ; Kellermeier, Fabian ; Dettmer, Katja

; Oefner, Peter J.

; Wichland, Marvin ; Ugele, Ines ; Bohr, Christopher ; Herr, Wolfgang ; Ramaswamy, Shivapriya ; Heinrich, Timo ; Herhaus, Christian ; Kreutz, Marina

; Renner, Kathrin

License: Creative Commons Attribution Non-commercial 4.0
PDF - Published Version
(4MB)

Date of publication of this fulltext: 26 Oct 2023 13:26

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Background & Aims Intratumoral lactate accumulation and acidosis impair T-cell function and antitumor immunity. Interestingly, expression of the lactate transporter monocarboxylate transporter (MCT) 4, but not MCT1, turned out to be prognostic for the survival of patients with rectal cancer, indicating that single MCT4 blockade might be a promising strategy to overcome glycolysis-related therapy ...